MARKET

RGEN

RGEN

Repligen Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

191.52
+1.52
+0.80%
After Hours: 191.52 0 0.00% 16:41 06/11 EDT
OPEN
191.37
PREV CLOSE
190.00
HIGH
192.97
LOW
189.60
VOLUME
248.62K
TURNOVER
--
52 WEEK HIGH
228.84
52 WEEK LOW
109.38
MARKET CAP
10.52B
P/E (TTM)
132.87
1D
5D
1M
3M
1Y
5Y
Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa
Zacks.com · 1d ago
Bristol Myers (BMY) Announces Data on CAR T Cell Therapy Breyanzi
Zacks.com · 1d ago
Vertex (VRTX) Ends Further Study on AAT Deficiency Candidate
Zacks.com · 1d ago
Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor
Zacks.com · 2d ago
Vertex's (VRTX) Trikafta Gets FDA Nod for CF in Children
The FDA approves Vertex's (VRTX) triple combination therapy, Trikafta, for treating cystic fibrosis in children aged between six to 11 years.
Zacks · 2d ago
Arena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE
Zacks.com · 2d ago
VBI Vaccines (VBIV) Up on Glioblastoma Drug Fast Track Status
VBI Vaccines (VBIV) is developing VBI-1901 as a potential treatment of recurrent glioblastoma patients.
Zacks · 3d ago
Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel
Arena (ARNA) is developing temanogrel in a phase II study as potential treatment for coronary microvascular obstruction in patients undergoing percutaneous coronary intervention.
Zacks · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RGEN. Analyze the recent business situations of Repligen Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RGEN stock price target is 238.86 with a high estimate of 251.00 and a low estimate of 200.00.
EPS
Institutional Holdings
Institutions: 578
Institutional Holdings: 51.99M
% Owned: 94.70%
Shares Outstanding: 54.90M
TypeInstitutionsShares
Increased
173
2.64M
New
69
1.05M
Decreased
151
2.90M
Sold Out
55
445.77K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.10%
Healthcare Equipment & Supplies
+0.06%
Key Executives
Chairman/Independent Director
Karen Dawes
President/Chief Executive Officer/Director
Tony Hunt
President/Chief Executive Officer/Director
Anthony Hunt
Chief Financial Officer
Jon Snodgres
Senior Vice President
James Bylund
Director
Carrie Eglinton
Senior Vice President
Christine Gebski
Senior Vice President
Ralf Kuriyel
Independent Director
Nicolas Barthelemy
Independent Director
Carrie Manner
Independent Director
Rohin Mhatre
Independent Director
Glenn Muir
Independent Director
Thomas Ryan
No Data
About RGEN
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Webull offers kinds of Repligen Corporation stock information, including NASDAQ:RGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RGEN stock methods without spending real money on the virtual paper trading platform.